BR112017019805A2 - composto, medicamento, composição farmacêutica, analgésico, antidepressivo, fármaco ansiolítico, métodos para melhorar, prevenir ou tratar dor, depressão, ansiedade, mal de parkinson, polaquiúria ou incontinência urinária e glaucoma, uso de um composto, agentes terapêuticos para mal de parkinson, para polaquiúria ou incontinência urinária e para glaucoma. - Google Patents

composto, medicamento, composição farmacêutica, analgésico, antidepressivo, fármaco ansiolítico, métodos para melhorar, prevenir ou tratar dor, depressão, ansiedade, mal de parkinson, polaquiúria ou incontinência urinária e glaucoma, uso de um composto, agentes terapêuticos para mal de parkinson, para polaquiúria ou incontinência urinária e para glaucoma.

Info

Publication number
BR112017019805A2
BR112017019805A2 BR112017019805-3A BR112017019805A BR112017019805A2 BR 112017019805 A2 BR112017019805 A2 BR 112017019805A2 BR 112017019805 A BR112017019805 A BR 112017019805A BR 112017019805 A2 BR112017019805 A2 BR 112017019805A2
Authority
BR
Brazil
Prior art keywords
similar
represent hydrogen
heterocycle
carbon atoms
carbon atom
Prior art date
Application number
BR112017019805-3A
Other languages
English (en)
Japanese (ja)
Other versions
BR112017019805B1 (pt
Inventor
Nagase Hiroshi
Fujii Hideaki
Saitoh Akiyoshi
Nakata Eriko
Hirose Masaaki
Ooi Isao
Hayashida Kohei
Original Assignee
University Of Tsukuba
School Juridical Person Kitasato Institute
National Center Of Neurology And Psychiatry
Nippon Chemiphar Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56919074&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017019805(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University Of Tsukuba, School Juridical Person Kitasato Institute, National Center Of Neurology And Psychiatry, Nippon Chemiphar Co., Ltd. filed Critical University Of Tsukuba
Publication of BR112017019805A2 publication Critical patent/BR112017019805A2/pt
Publication of BR112017019805B1 publication Critical patent/BR112017019805B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

os derivados de morfinano representados pela fórmula geral (i) (em que r1 representa hidrogênio, uma c1-10 alquila, uma cicloalquilalquila em que a porção cicloalquila tem 3-6 átomos de carbono e a porção alquileno tem 1-5 átomos de carbono, ou similares; r2 representa um heterociclo incluindo pelo menos um átomo de carbono e 1-4 heteroátomos selecionados dentre n, o e s como átomos anelares constituintes, com pelo menos um conjunto de átomos anelares constituintes adjacente tendo uma ligação dupla, referido heterociclo também incluindo pelo menos um grupo oxo como um substituinte; y é ligado a um átomo de carbono que é um átomo anelar constituinte de r2; r3, r4 e r5 representam hidrogênio, hidróxi ou similares; r6a e r6b representam hidrogênio ou similares; r7 e r8 representam hidrogênio ou similares; r9 e r10 são iguais ou diferentes, e representam hidrogênio ou similares; x representa o ou ch2; e y representa c(=o)), variantes e estereoisômeros dos derivados, sais farmaceuticamente aceitáveis dos mesmos e solvatos dos mesmos de acordo com a presente invenção são usados como fármacos ansiolíticos, antidepressivos e similares.
BR112017019805-3A 2015-03-17 2016-03-17 Composto, composição farmacêutica, e uso para fabricar uma composição farmacêutica para melhorar, prevenir ou tratar dor, ansiedade ou depressão, mal de parkinson, polaquiúria ou incontinência urinária e glaucoma BR112017019805B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015054079 2015-03-17
JP2015-054079 2015-03-17
PCT/JP2016/058475 WO2016148232A1 (ja) 2015-03-17 2016-03-17 モルヒナン誘導体

Publications (2)

Publication Number Publication Date
BR112017019805A2 true BR112017019805A2 (pt) 2018-05-29
BR112017019805B1 BR112017019805B1 (pt) 2023-01-31

Family

ID=56919074

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017019805-3A BR112017019805B1 (pt) 2015-03-17 2016-03-17 Composto, composição farmacêutica, e uso para fabricar uma composição farmacêutica para melhorar, prevenir ou tratar dor, ansiedade ou depressão, mal de parkinson, polaquiúria ou incontinência urinária e glaucoma

Country Status (24)

Country Link
US (4) US10442802B2 (pt)
EP (2) EP3974430A1 (pt)
JP (4) JP6692345B2 (pt)
KR (2) KR20230104767A (pt)
CN (3) CN113292558A (pt)
AU (2) AU2016234222C1 (pt)
BR (1) BR112017019805B1 (pt)
CA (1) CA2979023C (pt)
CY (1) CY1124908T1 (pt)
DK (1) DK3272750T3 (pt)
ES (1) ES2904511T3 (pt)
HK (1) HK1249900A1 (pt)
HU (1) HUE057266T2 (pt)
IL (1) IL254473B (pt)
MA (1) MA41790B1 (pt)
MX (2) MX2021008741A (pt)
MY (1) MY197742A (pt)
PH (1) PH12017501655B1 (pt)
PL (1) PL3272750T3 (pt)
RU (1) RU2762567C2 (pt)
SG (2) SG11201707427TA (pt)
TW (2) TWI775723B (pt)
WO (1) WO2016148232A1 (pt)
ZA (1) ZA201706882B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2018030382A1 (ja) 2016-08-09 2019-06-13 日本ケミファ株式会社 モルヒナン誘導体
EP3513792B1 (en) 2016-09-16 2024-03-27 Nippon Chemiphar Co., Ltd. Morphinan derivatives for the treatment of opioid delta receptor agonist-related diseases
JP7283711B2 (ja) * 2016-10-03 2023-05-30 学校法人星薬科大学 モルヒナン誘導体を含む医薬組成物及びその鎮痛剤への使用
US20220267327A1 (en) 2019-07-19 2022-08-25 Nippon Chemiphar Co., Ltd. Method for producing morphinan derivative
JPWO2021015109A1 (pt) 2019-07-19 2021-01-28
EP4206203A1 (en) 2020-08-28 2023-07-05 Nippon Chemiphar Co., Ltd. Method for preparing morphinan derivative having diaryl ether skeleton using novel copper catalyst

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005231995A (ja) 1999-12-22 2005-09-02 Meiji Seika Kaisha Ltd オピオイドδ受容体アゴニスト／アンタゴニストとして有用なスピロ化合物
DE10161963A1 (de) 2001-12-17 2003-07-03 Johannes Schuetz 6-Aminomorphinanderivate, Herstellungsverfahren dafür und deren Verwendung
AR044010A1 (es) 2003-04-11 2005-08-24 Janssen Pharmaceutica Nv Uso de derivados de 4-fenil-4- [1h-imidazol-2-il]- piperidina sustituidos como agonistas delta opioideos no peptidos selectivos, con actividad antidepresiva y ansiolitica
WO2006107254A1 (en) 2005-04-04 2006-10-12 Astrazeneca Ab Novel diazaspiroalkanes and their use for treatment of ccr8 mediated diseases
JPWO2008001859A1 (ja) 2006-06-30 2009-11-26 学校法人北里研究所 オピオイドδ受容体アゴニスト
CA2698753A1 (en) 2007-09-06 2009-03-12 Array Biopharma Inc. Pyrazolo-pyridines as tyrosine kinase inhibitors
AU2010313392B2 (en) 2009-10-30 2015-07-09 Janssen Pharmaceutica Nv Pyrazines as delta opioid receptor modulators
EP2525659B1 (en) 2010-01-19 2019-02-27 Merck Sharp & Dohme Corp. PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS
JP6091426B2 (ja) 2010-12-23 2017-03-08 フェニックス ファーマラブス インク 鎮痛剤として有用な新規モルフィナン類
JP2014073964A (ja) 2011-01-28 2014-04-24 Kitasato Institute モルヒナン誘導体
JP6061857B2 (ja) * 2011-09-09 2017-01-18 学校法人北里研究所 モルヒナン誘導体
WO2014021273A1 (ja) 2012-07-30 2014-02-06 学校法人北里研究所 モルヒナン誘導体
US8937084B2 (en) 2012-12-14 2015-01-20 Purdue Pharma L.P. Nitrogen containing morphinan derivatives and the use thereof
EP2966074B1 (en) 2013-03-08 2018-07-25 The Kitasato Institute Morphinan derivative
EP3513792B1 (en) 2016-09-16 2024-03-27 Nippon Chemiphar Co., Ltd. Morphinan derivatives for the treatment of opioid delta receptor agonist-related diseases

Also Published As

Publication number Publication date
JP6692345B2 (ja) 2020-05-13
CN113292559A (zh) 2021-08-24
EP3272750A4 (en) 2018-08-08
RU2017134286A (ru) 2019-04-05
AU2020270503A1 (en) 2020-12-17
JP2022081656A (ja) 2022-05-31
CY1124908T1 (el) 2023-01-05
SG11201707427TA (en) 2017-10-30
AU2016234222A1 (en) 2017-10-26
AU2016234222C1 (en) 2021-02-11
AU2020270503B2 (en) 2023-02-02
TWI775723B (zh) 2022-09-01
TW202244044A (zh) 2022-11-16
US11643411B2 (en) 2023-05-09
US10995092B2 (en) 2021-05-04
AU2016234222B2 (en) 2020-08-27
CN107614500A (zh) 2018-01-19
KR20230104767A (ko) 2023-07-10
WO2016148232A1 (ja) 2016-09-22
RU2017134286A3 (pt) 2019-04-19
EP3974430A1 (en) 2022-03-30
MX2017011824A (es) 2018-04-20
TW201638089A (zh) 2016-11-01
RU2762567C2 (ru) 2021-12-21
MY197742A (en) 2023-07-12
MX2021008741A (es) 2022-11-01
AU2020270503C9 (en) 2024-02-29
CN113292558A (zh) 2021-08-24
KR20180002616A (ko) 2018-01-08
US20180057493A1 (en) 2018-03-01
IL254473B (en) 2022-05-01
JP2024010098A (ja) 2024-01-23
AU2020270503C1 (en) 2023-08-10
MA41790B1 (fr) 2022-02-28
JP7375076B2 (ja) 2023-11-07
EP3272750B1 (en) 2021-11-03
US20210040094A1 (en) 2021-02-11
HUE057266T2 (hu) 2022-05-28
KR102551969B1 (ko) 2023-07-05
CN107614500B (zh) 2021-06-15
PL3272750T3 (pl) 2022-03-07
IL254473A0 (en) 2017-11-30
US20230159530A1 (en) 2023-05-25
ZA201706882B (en) 2022-02-23
CA2979023C (en) 2023-09-26
US10442802B2 (en) 2019-10-15
CN113292559B (zh) 2024-04-02
EP3272750A1 (en) 2018-01-24
SG10201907667RA (en) 2019-09-27
TWI778933B (zh) 2022-09-21
US20200079775A1 (en) 2020-03-12
AU2020270503B9 (en) 2023-10-12
BR112017019805B1 (pt) 2023-01-31
MA41790A (fr) 2021-06-02
HK1249900A1 (zh) 2018-11-16
PH12017501655A1 (en) 2018-03-12
CA2979023A1 (en) 2016-09-22
PH12017501655B1 (en) 2018-03-12
DK3272750T3 (en) 2022-01-03
JP2020117533A (ja) 2020-08-06
JPWO2016148232A1 (ja) 2018-03-08
ES2904511T3 (es) 2022-04-05

Similar Documents

Publication Publication Date Title
BR112017019805A2 (pt) composto, medicamento, composição farmacêutica, analgésico, antidepressivo, fármaco ansiolítico, métodos para melhorar, prevenir ou tratar dor, depressão, ansiedade, mal de parkinson, polaquiúria ou incontinência urinária e glaucoma, uso de um composto, agentes terapêuticos para mal de parkinson, para polaquiúria ou incontinência urinária e para glaucoma.
UY37795A (es) Sulfonilureas y sulfoniltioureas útiles como inhibidores de nlrp3
AR109349A1 (es) Compuestos y usos
CL2018003701A1 (es) Compuestos heterocíclicos como inmunomoduladores.
AR109348A1 (es) Sulfonilureas y compuestos relacionados y sus usos
PH12016501440A1 (en) Novel heterocyclic compounds
DOP2016000299A (es) Derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y su uso como inhibidores ido1
MX2019003887A (es) Compuestos, dispositivos y usos de los mismos.
AR100251A1 (es) Inhibidores de la dematilasa-1 especifica de lisina
CL2019001495A1 (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih.
AR110789A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
BR112017013677A2 (pt) compostos macrocíclicos como inibidores de irak1/4 e usos dos mesmos
AR110790A1 (es) Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)
MX2021006274A (es) Derivados cíclicos de panteteína y usos de los mismos.
BR112017022654A2 (pt) derivado heterocíclico de 6 membros e composição farmacêutica compreendendo o mesmo
MA39956A (fr) Analogues du benzomorphane et leur utilisation
CO2018010787A2 (es) Compuesto de griseofulvina
PH12019501178A1 (en) Thiopene derivatives as antiviral agents
EA201890448A1 (ru) Фумагиллиновые спироциклические соединения и конденсированные бициклические соединения и способы их получения и применения
BR112015017740A2 (pt) composto heterocíclico condensado
TR201900659T4 (tr) Mineralokortikoid reseptör modülatörleri olarak benzoksazinon amidleri.
MX2017011978A (es) Analogos deuterados de etifoxina, sus derivados y usos de estos.
BR112017028125A2 (pt) derivado de pirazola ou sal farmaceuticamente aceitável do mesmo
AR109467A1 (es) Compuestos, procedimiento de obtención de los compuestos, composición farmacéutica, uso de los compuestos y método de tratamiento de desórdenes psiquiátricos y/o trastornos del sueño
EA201792109A1 (ru) Конденсированные с тетрагидрофураном производные аминогидротиазина, пригодные для лечения болезни альцгеймера

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: SCHOOL JURIDICAL PERSON KITASATO INSTITUTE (JP) ;

B25A Requested transfer of rights approved

Owner name: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) ; NIPPON CHEMIPHAR CO., LTD. (JP)

Owner name: NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) ;

B25A Requested transfer of rights approved

Owner name: NIPPON CHEMIPHAR CO., LTD. (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 17/03/2016, OBSERVADAS AS CONDICOES LEGAIS